News | July 31, 2013

MRI Detects Early Effects of Chemotherapy on Children's Hearts

July 31, 2013 — Magnetic resonance imaging (MRI) scans of children who have had chemotherapy can detect early changes in their hearts, according to research findings in BioMed Central's open access journal Journal of Cardiovascular Magnetic Resonance.

Chemotherapy with anthracyclines, such as Doxorubicin, is one of the most effective treatments against many types of cancer, including leukemia and Hodgkin's lymphoma, breast, lung and ovarian cancer. However it can also lead to irreversible heart damage, which may not be apparent until several years after treatment. Being able to detect this damage at an early stage, in order to initiate preventative therapy of affected people, is especially important in children.

Researchers from the University of Alberta performed MRI scans on children and young adults (aged 7 to 19) at the Stollery Children's Hospital who were in remission following anthracycline treatment. They found that they were able to identify changes in heart muscle related to the formation of fibrosis, using an emerging MRI method called T1 mapping, even in children whose heart function was apparently normal by ultrasound.

The study funded by the Women's and Children's Health Research Institute led by Edythe Tham, M.D., and Richard Thompson, M.D., said: "In childhood cancer survivors, MRI changes were related to anthracycline dose given to the children. These changes are also mirrored by thinning of the heart wall and a reduction in the exercise capacity. By detecting these changes early we can only hope that future research using these techniques may guide early identification and treatment in attempts to delay the onset of heart damage in children who have survived cancer."

For more information: www.biomedcentral.com

Related Content

GE Healthcxare Signa Pioneer MAGIC six contrasts in one scan software by SyntheticMR.

The MRI software enables several different contrasts to be obtained from one scan, shortening scan times.

Feature | Magnetic Resonance Imaging (MRI)| August 31, 2017
August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI.
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
GE Healthcare's Signa Premier MRI Receives FDA 510(k) Clearance
Technology | Magnetic Resonance Imaging (MRI)| August 04, 2017
GE Healthcare announced Signa Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available...
Cardiac CT scan showing plaque and calcification in the coronary arteries, from a Toshiba CT scanner
News | Business| July 19, 2017
July 19, 2017 — The Society of Cardiovascular Computed Tomography (SCCT) created a reimbursement fee chart for cardia
German Workshop Highlights Possibilities of Perfusion MRI
News | Stroke| July 03, 2017
When diagnosing strokes and heart diseases or looking at tumors, perfusion magnetic resonance imaging (MRI) offers a...
Sponsored Content | Videos | Clinical Decision Support| June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Toshiba Medical Introduces Vantage Titan Zen Edition MR
Technology | Magnetic Resonance Imaging (MRI)| June 27, 2017
June 27, 2017 — Toshiba Medical, a Canon Group company, introduced its newest...
Overlay Init